The Personnel-Hours Question in Psychedelic Therapy

For payers and analysts, the practical economic unit in psychedelic therapy is not simply a dose, a session, or a course of treatment. It is supervised human time: preparation, acute-session support, integration, medical oversight, crisis planning, documentation, and follow-up. The drug may be clinically distinctive, but the access question often turns on how much scarce professional labour the protocol requires.

What the evidence map is trying to answer

This resource uses one recurring question: how many hours, delivered by which personnel, for how many patients? Clinical trials often report session counts, but reimbursement and capacity planning need a more operational denominator: staff-hours per treated patient.

A one-session psychedelic treatment can sound operationally light until the service model is made explicit. The patient may experience one dosing day, but the provider may need psychiatric screening, medication review, several preparation contacts, two clinicians in the room for most of a day, post-session observation, integration sessions, documentation, supervision, and a pathway back into ordinary care. For access planning, those pieces should not be collapsed into a single headline session count.

The evidence map is a translation exercise. The first layer is clinical: what did the protocol ask staff to do? The second layer is operational: how many staff-hours does that imply under individual, paired, or group delivery? The third layer is economic: which of those hours must be delivered by scarce and expensive personnel in a given country, and which could safely be shifted to lower-cost roles under supervision?

Three denominators are useful throughout. Patient-facing hours describe what the participant experiences in preparation, dosing support, integration, or follow-up. Staff-hours multiply that contact time by the number and type of staff present. System-hours add the surrounding work that is easy to miss in trial write-ups: prescribing, screening, documentation, training, supervision, facilities, adverse-event response, and programme coordination.

The formula is deliberately simple because it separates three things that are often blurred. Session hours describe what the patient receives. Staff-hours describe what the service must staff. Total cost then adds role-specific wages, facilities, medicine cost, training, supervision, insurance, documentation, and payer overhead. A neutral model should keep those layers separate before making any claim about affordability.

The care pathway

Across modern psychedelic-assisted therapy protocols, the structure is surprisingly consistent even when the drug, indication, and therapeutic frame differ.

The pathway usually starts with screening and eligibility: psychiatric and medical history, contraindications, medication review, suicide and psychosis risk, consent, and treatment planning. Preparation then builds the therapeutic alliance, expectations, safety plan, and practical skills for navigating difficult material. The dosing or acute-support session is the most visible component, but integration and follow-up are what reconnect the experience to ordinary care through debriefing, meaning-making, behaviour change, outcome assessment, adverse-event review, and escalation if symptoms worsen.

For payers, this pathway matters because not every hour has the same cost or governance implication. For researchers, it matters because missing protocol details make later economic modelling fragile. A study that reports only "one dosing session" gives much less implementation information than a study that reports preparation time, acute staffing ratio, integration intensity, follow-up contacts, and who delivered each element.

Blossom now also has a clinical-guidelines library that indexes trial-linked guidance and extracted competencies. The hours model should be read alongside that competency layer, because "who can sit in the room" is a clinical governance question as much as a cost question.

Database evidence snapshot

The evidence scan includes 10 health-economics or cost-related paper records, 10 trial records with structured preparation/dosing/integration fields, and 10 clinical-guideline records. Those internal records anchor the protocol and competency assumptions before local implementation choices are added.

Representative internal paper records

Representative trial-hour records

Representative clinical-guideline records

Protocol archetypes from the current evidence base

These ranges are not universal treatment recommendations. They are working archetypes for reading the literature and turning protocols into comparable staff-hour models.

MDMA-assisted therapy for PTSD

Modern MDMA-assisted therapy is the high-hour archetype. The conceptual framework used in phase 3 MDMA trials describes three 90-minute preparation sessions, two to three 8-hour experimental sessions, and repeated 90-minute integration sessions. With a two-therapist model, three 8-hour sessions alone can imply 48 staff-hours of acute-session coverage before preparation and integration are counted.

Psilocybin-assisted therapy for depression or TRD

Contemporary psilocybin therapy usually follows preparation, dosing, and integration. A recent mapping review summarises preparation as roughly 1-5 sessions or 2-8 hours, dosing as 1-3 sessions lasting 4-10 hours each, and integration as 2-8 sessions or 2-12 hours. Sloshower and colleagues provide a concrete ACT-framed example: two psilocybin dosing days, preparatory sessions before each, debriefing after each, and follow-up sessions, with about 16-20 therapy hours excluding the dosing days themselves. Blossom trial records already contain structured fields for preparation, dosing, and integration session counts and durations, so this section can be periodically refreshed from the database rather than rewritten from scratch.

Group-format psychedelic therapy

Ilinca's preliminary review usefully points to both historical and modern group models. The older group LSD literature shows that group delivery has been part of psychedelic therapy since the first wave, especially in alcoholism and mixed psychiatric settings. The HOPE psilocybin cancer trial is the clearest modern scaffold in the attached document: three 120-minute group preparation sessions, one high-dose group psilocybin session, and three 120-minute group integration sessions, with a 1:1 therapist-to-participant ratio during the dosing session. Group therapy can reduce per-patient staff-hours when preparation and integration are shared, but that effect depends on group size, dosing-session staffing ratio, participant acuity, and whether individual sessions are still required.

Ketamine, esketamine, and shorter-acting models

Ketamine and esketamine models are useful comparators because repeated dosing and medical monitoring can dominate the time model even when psychotherapy is lighter or absent. Short-acting DMT or 5-MeO-DMT models could reduce acute-session coverage hours, but they do not automatically remove screening, preparation, integration, prescribing, or risk-management labour.

A staff-hours worksheet

For each protocol, a useful worksheet needs the same columns: compound and indication; evidence source; preparation sessions and duration; dosing sessions and duration; integration and follow-up; staffing ratio; patient-facing hours; staff-hours; notes on medical oversight.

The worksheet is an audit trail rather than a final price. It shows where the hours enter the model, which assumptions are pulled from a trial protocol, and which assumptions are implementation choices. This matters because two services can both describe themselves as psilocybin-assisted therapy while using different screening rules, different preparation intensity, different dosing-room staffing, and different expectations about ongoing psychotherapy.

Protocol-hours comparison table

The point of the table is not to imply that one model is always better. It is to make the bottleneck visible. MDMA-AT is dominated by long, highly staffed acute sessions; psilocybin models are dominated by full-day coverage and the surrounding therapy frame; group psilocybin shifts the question toward group size and dosing-room ratio; ketamine shifts attention toward repeated visits, medical monitoring, and clinic throughput.

The payer-facing interpretation is that the same evidence of clinical benefit can imply very different delivery constraints. A protocol with fewer dosing days may still be expensive if it requires senior clinicians before and after treatment. A protocol with shorter acute sessions may still be capacity-limited if repeated monitoring visits are needed. The table therefore helps identify which part of the care model should be priced, staffed, or studied more carefully.

Which personnel are actually needed?

The personnel question should be separated into clinical accountability, therapeutic delivery, acute monitoring, and programme operations. One person may cover more than one role, but reimbursement and workforce planning should not hide those functions.

Personnel-role table

The table is a reminder that "therapist hours" is too blunt for reimbursement analysis. A psychiatrist hour, a psychologist hour, a nurse-monitoring hour, a trained-facilitator hour, and a programme-coordination hour may all be necessary, but they have different costs, scarcity constraints, professional rules, and substitution possibilities. A credible model should identify the function first and only then ask which professional can safely and legally perform it in a specific system.

Regional examples: why the same protocol costs different amounts

The hours may be broadly similar across countries, but the cost and feasibility of those hours are not. The region-specific question is which professional must perform or supervise each task, what that labour costs, and whether payers recognise the work.

Regional cost translation table

Regional translation should start from the same staff-hour denominator and then change the local assumptions. Wage baselines, reimbursement logic, professional scope, and service setting can move the final estimate even when the clinical protocol is unchanged. The examples below are therefore not legal summaries; they show how a payer or analyst might structure country-specific assumptions.

United States

In the United States, BLS wage data is the public baseline for psychiatrists, psychologists, nurses, and social workers. Reimbursement modelling would then need to translate those wages into billed service prices, including clinic overhead, malpractice and compliance costs, coding assumptions, and any risk-management requirements attached to an approved product. The likely bottleneck is not only therapist time but medically accountable supervision, prescribing, emergency governance, and payer recognition of non-standard session lengths. The main update point is that FDA labels, REMS-like controls, CPT coding, and payer policies could materially change which hours are reimbursable.

United Kingdom

In the United Kingdom, NHS modelling should start with Agenda for Change bands for psychologists, nurses, therapists, and coordinators, plus medical and dental pay scales for psychiatrists. A NICE-style assessment would then place those staff-hours against incremental cost per QALY, durability of effect, service capacity, and comparators such as CBT, antidepressants, ECT, ketamine, or specialist PTSD care. The likely bottleneck is protected specialist time inside services that are already capacity-constrained. The uncertainty is whether a future pathway would sit in ordinary mental-health services, specialist centres, research-linked clinics, or a mixed model.

Germany

Germany is a useful example for separating statutory reimbursement, physician involvement, psychotherapy provision, and clinic tariff logic. Collective-pay tables can anchor public-sector labour assumptions, but statutory care, hospital tariffs, private psychotherapy, and specialist clinic delivery may produce different prices for the same staff-hour worksheet. The personnel bottleneck is likely to sit around physician accountability, licensed psychotherapy provision, and whether acute-session support can be delegated. The update point is pathway-specific: a model embedded in existing reimbursed psychotherapy would not have the same cost structure as a specialised centre.

Netherlands

For Dutch modelling, CAO GGZ 2025-2026 is the natural labour-cost baseline for mental-health institutions. Reimbursement logic would need to fit psychedelic therapy into specialist mental-health pathways rather than treating retreat availability as a proxy for reimbursable care. The personnel bottleneck is likely to be GZ-psychologist, psychotherapist, psychiatrist, and specialist-nurse capacity inside an already stretched GGZ system. The uncertainty is whether psychedelic therapy would add a new specialist layer or be integrated into existing pathways with training, supervision, and referral criteria.

Czech Republic

Czechia deserves a separate note because 2025 legislative changes and public statements point toward clinical psilocybin-assisted therapy introduction from 2026. Until mature reimbursement tariffs exist, labour assumptions will likely depend on provider-level staffing models, psychiatrist involvement, psychotherapist availability, and medical monitoring requirements. The bottleneck may therefore be pathway formation itself: which teams are authorised, what training is expected, and how psychotherapy requirements are specified. The update point is unusually live, because legal access may become clearer before stable payer rules do.

What changes the answer most?

The most important sensitivity analyses are not obscure statistical parameters. They are concrete service-design choices: the number of dosing sessions, the staffing ratio during acute sessions, the amount of individual support retained around a group model, and the durability of clinical benefit. These assumptions determine whether psychedelic therapy looks like a specialised high-intensity intervention for a narrow population or a scalable treatment model that public systems could plausibly adopt.

Moving from one to two or three acute sessions can dominate staff-hours. A two-therapist or 1:1 group dosing model changes cost more than small changes in preparation length. Group size can reduce per-patient preparation and integration hours, but only if safety, cohesion, and individual clinical needs remain manageable. Personnel substitution may reduce cost, but only where regulation, evidence, supervision, and governance permit it. Finally, durability, retreatment, adverse events, and dropout rates can change the economic conclusion even when the initial protocol looks efficient.

Information payers need before coverage modelling

Before coverage modelling, payers need more than an efficacy estimate. They need to understand the service that produced that estimate: the staff mix, time requirements, monitoring obligations, retreatment expectations, adverse-event pathway, and comparator care displaced or added.

A neutral payer-facing model should be able to answer five questions. How many staff-hours are required per treated patient under the labelled or reimbursed protocol? Which hours require licensed specialists, and which can be safely delivered by other trained staff? How durable are benefits, and how often will patients need retreatment or stepped follow-up? Does group, hybrid, or stepped-care delivery preserve outcomes while changing the workforce bottleneck? What existing care does the intervention replace or add to: medication management, psychotherapy, inpatient care, crisis contacts, disability costs, or productivity losses?

None of those questions settles coverage on its own. They make the budget-impact and capacity conversation explicit. A therapy can be clinically promising and still difficult to commission if it depends on scarce staff in ways that ordinary session counts hide.

What researchers and analysts should extract

For researchers and analysts, the staff-hours question becomes an extraction discipline. Trial reports, protocols, manuals, and clinical-guideline records should be read for operational details that can later support reimbursement, capacity, and implementation models.

The most useful extraction fields are preparation sessions and duration; dosing or acute-support sessions and duration; integration sessions and duration; follow-up contacts; staff ratio during acute sessions; professional roles and supervision requirements; group size; individual support retained inside group models; adverse-event monitoring and escalation; dropout; retreatment; durability of benefit; and the comparator pathway. When those fields are missing, analysts should label the resulting staff-hours estimate as an assumption rather than an evidence-derived value.

Explore the staff-hours model

Small changes in protocol design can move staff-hours more than the choice of country or wage source. The worksheet below keeps those assumptions visible: preparation intensity, number and length of dosing sessions, acute-session staffing, integration, group size, and blended labour cost. The output should be read as a sensitivity check, not a tariff.

Care-pathway hours stack

The hours stack separates preparation, dosing support, integration, and the effect of shared sessions. An 8-hour dosing day is not 8 hours of system labour when two staff are present and when pre/post work is counted.

Protocol comparison matrix

The protocol matrix places MDMA-AT, psilocybin-AT, group psilocybin, and ketamine-assisted psychotherapy on the same axis. The comparison is intentionally coarse: it is meant to show where each model puts pressure on the workforce before more precise local assumptions are added.

Staff-hours calculator

The calculator converts abstract service design into a denominator that can be priced. Staff-hours per treated patient is not the full cost of care, but it is the missing bridge between trial protocol and payer-facing budget impact.

Regional wage translator

The wage translator applies rough country-specific labour assumptions for the United States, United Kingdom, Germany, Netherlands, and Czech Republic. It separates labour from medicine cost, facility overhead, training, supervision, and payer margin, so the output is not mistaken for a complete tariff.

Group-size sensitivity

The group-size slider shows where group delivery actually saves therapist time and where it does not. This avoids the common overclaim that group therapy is automatically cheaper, while still showing why it may be essential for workforce capacity.

Keeping the model current

The durable layer is the care-phase model: screening, preparation, acute support, integration, follow-up, risk monitoring, and the distinction between patient-facing hours and staff-hours. Those categories should remain useful even as specific compounds, protocols, and reimbursement decisions change.

The refreshable layers are the protocol-hours worksheet, role assumptions, wage baselines, country-specific regulation, clinical-guideline records, durability and retreatment assumptions, and payer interpretation. Blossom can update the worksheet from structured trial fields and full-text protocol review after major publications, use the clinical-guidelines library to revise personnel and competency assumptions when new manuals or SOPs are added, date-stamp regional cost assumptions, and keep stakeholder interviews separate from evidence-derived protocol assumptions.

Sources and update points

The evidence base draws on Ilinca Gavril's preliminary review document, Blossom trial and paper records, Blossom clinical-guidelines infrastructure, and the external sources below. These links are the first places to check when protocol, wage, or regulatory assumptions change.

• Group therapy background: Trope et al. (2019), Psychedelic-Assisted Group Therapy: A Systematic Review.

• Modern group psilocybin example: Lewis et al. (2023), observations from the HOPE trial.

• MDMA therapy framework: O'Donnell et al. (2024), phase 3 therapeutic approach.

• Psilocybin therapy mapping: Kittur et al. (2025), therapeutic frameworks across contemporary trials.

• ACT psilocybin frame: Sloshower et al. (2019), psilocybin-assisted therapy using Acceptance and Commitment Therapy.

• Group delivery economics: Marseille et al. (2023), empirical estimates of cost savings and improved access.

• US wage baseline: Bureau of Labor Statistics occupational wage data.

• UK wage baseline: NHS Employers pay scales for 2025/26.

• Netherlands wage baseline: CAO GGZ 2025-2026.

• Czech regulatory watch point: National Institute of Mental Health statement on psilocybin treatment availability.